Stockhub

Editing Anastasis Biotec

Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.

The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.

Latest revision Your text
Line 1: Line 1:
==Summary==
== Summary ==


Following research at Imperial College, we believe we’ve found a novel and effective treatment for relapsed/resistant cancer, targeting and killing cancer stem cells. With patents in place, we now need funding for the next phase: to complete lab-testing prior to clinical trials.
Following research at Imperial College, we believe we’ve found a novel and effective treatment for relapsed/resistant cancer, targeting and killing cancer stem cells. With patents in place, we now need funding for the next phase: to complete lab-testing prior to clinical trials.* Novel and proprietary cancer treatment for relapsed/resistant cancer* Can kill cancer stem cells, one of the engines of cancer resistance and relapse* Strong scientific foundation developed at Imperial College, London* Commercially-experienced team with deep oncology knowledge==Idea==<vimeo>424748467</vimeo>Cancer is a major cause of death, killing 9.6m people in 2018. We are developing a human protein-based therapeutic product, Syntana-4 (S-4), which inhibits cancer stem cells (CSC) - the growth engine of cancer.If clinical trials are successful, S-4 could provide a desperately needed treatment option for many relapsed/resistant tumours with ‘Notch’ mutations.The global cancer drug market was at ~$200bn in 2019. S-4 would initially target use for patients with relapsed prostate cancer, which caused 3.8% of global cancer deaths in 2018. Our research indicates that S-4 could help provide a solution to combat this deadly disease.Alongside this, our research suggests S-4 will have low manufacturing costs, making it affordable, enabling ‘mass market’ sales strategy.We have secured the rights and patents related to the delivery platform for CSC and other tissue, based on a cell-penetrating protein (ANTP) which can deliver drugs into the nucleus of cells.We have raised £450k in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award and are now looking to raise to progress S-4 in collaboration with the University of Chicago’s current cancer stem cell therapeutics R&D program (partnership is pending signature).Key milestones are to complete all steps to a phase II clinical trial, demonstrate clinical efficacy and then secure an exit through M&A.==Team==The core team:'''Prof. Agamemnon Epenetos, Chairman and Chief Executive Officer'''He is a successful biotechnology entrepreneur and qualified medical oncologist who has previously developed new drugs through to commercial production.'''Mr. Laurence Cohen, Part-time Company Secretary and Director'''Solicitor, formerly a Global Head of IP at Latham & Watkins, with expertise in legal, IPR, corporate governance and fund raising logistics. Consultant to a funding introducer for Phase 2 clinical trials.'''Dr. Mahendra Deonarain, Part-time Chief Operating Officer'''Oversees research and development, financial and logistical activities of the Company. He is involved in successful biotech start-ups and is a director of a commercial R&D laboratory.'''Prof. Raymond Moellering, Part-time Chief Scientific Officer'''Brings expertise on protein chemistry research and development.'''Matthew Cohen, Part-time'''Qualified Accountant with M&A and investor relations experience in a FTSE 100 company.The team is highly diverse and experienced, with a balance of scientific, medical and business skills. They have the requisite skills and expertise to successfully implement the Company’s plans through to commercial fruition.Anastasis was set up from pioneering R&D at Imperial College. The team are motivated to produce an effective cancer treatment for the benefit of society as a whole.[[Category:Thesis]][[Category:Equities]]


* Novel and proprietary cancer treatment for relapsed/resistant cancer
* Can kill cancer stem cells, one of the engines of cancer resistance and relapse
* Strong scientific foundation developed at Imperial College, London
* Commercially-experienced team with deep oncology knowledge
==Idea==
<vimeo>424748467</vimeo>
Cancer is a major cause of death, killing 9.6m people in 2018. We are developing a human protein-based therapeutic product, Syntana-4 (S-4), which inhibits cancer stem cells (CSC) - the growth engine of cancer.
If clinical trials are successful, S-4 could provide a desperately needed treatment option for many relapsed/resistant tumours with ‘Notch’ mutations.
The global cancer drug market was at ~$200bn in 2019. S-4 would initially target use for patients with relapsed prostate cancer, which caused 3.8% of global cancer deaths in 2018. Our research indicates that S-4 could help provide a solution to combat this deadly disease.
Alongside this, our research suggests S-4 will have low manufacturing costs, making it affordable, enabling ‘mass market’ sales strategy.
We have secured the rights and patents related to the delivery platform for CSC and other tissue, based on a cell-penetrating protein (ANTP) which can deliver drugs into the nucleus of cells.
We have raised £450k in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award and are now looking to raise to progress S-4 in collaboration with the University of Chicago’s current cancer stem cell therapeutics R&D program (partnership is pending signature).
Key milestones are to complete all steps to a phase II clinical trial, demonstrate clinical efficacy and then secure an exit through M&A.
==Team==
The core team:
'''Prof. Agamemnon Epenetos, Chairman and Chief Executive Officer'''
He is a successful biotechnology entrepreneur and qualified medical oncologist who has previously developed new drugs through to commercial production.
'''Mr. Laurence Cohen, Part-time Company Secretary and Director'''
Solicitor, formerly a Global Head of IP at Latham & Watkins, with expertise in legal, IPR, corporate governance and fund raising logistics. Consultant to a funding introducer for Phase 2 clinical trials.
'''Dr. Mahendra Deonarain, Part-time Chief Operating Officer'''
Oversees research and development, financial and logistical activities of the Company. He is involved in successful biotech start-ups and is a director of a commercial R&D laboratory.
'''Prof. Raymond Moellering, Part-time Chief Scientific Officer'''
Brings expertise on protein chemistry research and development.
'''Matthew Cohen, Part-time'''
Qualified Accountant with M&A and investor relations experience in a FTSE 100 company.
The team is highly diverse and experienced, with a balance of scientific, medical and business skills. They have the requisite skills and expertise to successfully implement the Company’s plans through to commercial fruition.
Anastasis was set up from pioneering R&D at Imperial College. The team are motivated to produce an effective cancer treatment for the benefit of society as a whole.
[[Category:Thesis]]
[[Category:Equities]]
__INDEX__
__INDEX__
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see Stockhub:Copyrights for details). Do not submit copyrighted work without permission!
Cancel Editing help (opens in new window)
Retrieved from ‘https://stockhub.co/research/Anastasis_Biotec’